Effect of Peginterferon Beta-1a on MRI Measures in RRMS
Analyses of MRI outcomes and NEDA, along with efficacy for single clinical endpoints reported previously, support SC peginterferon beta-1a every 2 weeks as an effective treatment option for patients with RRMS, with the benefit of less frequent administration.
Conclusion
Analyses of MRI outcomes and NEDA, along with efficacy for single clinical endpoints reported previously, support SC peginterferon beta-1a every 2 weeks as an effective treatment option for patients with RRMS, with the benefit of less frequent administration.
SHARE
